Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine

Clin Infect Dis. 2008 Feb 1;46(3):e28-30. doi: 10.1086/525857.

Abstract

We summarize the clinical history and laboratory results following the introduction of tenofovir among 6 patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with severe liver disease while receiving lamivudine-based highly active antiretroviral therapy. In all cases, the introduction of tenofovir led to a sustained undetectable HBV and HIV loads, with marked clinical and laboratory improvement in liver function. We provide supporting evidence for the role of tenofovir in the management of advanced HBV infection in HIV-positive patients after the development of lamivudine resistance.

Publication types

  • Case Reports

MeSH terms

  • Adenine / administration & dosage
  • Adenine / adverse effects
  • Adenine / analogs & derivatives*
  • Adult
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / adverse effects
  • Antiretroviral Therapy, Highly Active / methods
  • Drug Resistance, Viral
  • HIV / isolation & purification
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • Hepatitis B virus / isolation & purification
  • Hepatitis B, Chronic / drug therapy*
  • Hepatitis B, Chronic / virology
  • Homosexuality, Male
  • Humans
  • Lamivudine / administration & dosage*
  • Lamivudine / adverse effects
  • Liver Diseases / drug therapy*
  • Liver Diseases / metabolism
  • Liver Diseases / virology*
  • Male
  • Organophosphonates / administration & dosage*
  • Organophosphonates / adverse effects
  • Tenofovir
  • Transaminases / metabolism
  • Viral Load

Substances

  • Anti-HIV Agents
  • Organophosphonates
  • Lamivudine
  • Tenofovir
  • Transaminases
  • Adenine